Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.

已完结 10 由 Aixuexi 发布于 2026/1/4 10:42:17

DOI:10.1016/S1470-2045(21)00073-5
作者：Andrés Poveda,?Anne Floquet,?Jonathan A Ledermann,?Rebecca Asher,?Richard T Penson,?Amit M Oza,?Jacob Korach,?Tomasz Huzarski,?Sandro Pignata,?Michael Friedlander,?Alessandra Baldoni,?Tjoung-Won Park
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：Background: Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has previously been shown to extend progression-free survival versus placebo when given to patients with relapsed high-

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:SpringerEnhancing vaccine stability in transdermal microneedle platforms.